Left at the Altar: No Buyout for This Health-Care Giant

For those following the health-care sector, there's no doubt that 2013 will be known as the year of the spinoff. However, the year started out with rampant speculation that another big acquisition was in the cards -- private equity firm Warburg Pincus was looking for a liquidity event for eye-care specialist Bausch & Lomb.

The potential price: $10 billion. The potential suitors: Abbott Labs (NYSE: ABT  ) , Johnson & Johnson (NYSE: JNJ  ) , Merck (NYSE: MRK  ) , Pfizer (NYSE: PFE  ) , and Sanofi (NYSE: SNY  ) . Follow along in the video below as Brenton Flynn runs through the likely final result.

Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out The Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy, and a year of free analyst updates, by clicking here now.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2272412, ~/Articles/ArticleHandler.aspx, 4/24/2014 1:46:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement